Follow-up Recommendations for Completely Resected Gastroenteropancreatic Neuroendocrine Tumors

Simron Singh, Lesley Moody, David L. Chan, David C. Metz, Jonathan Strosberg, Timothy Asmis, Dale L. Bailey, Emily Bergsland, Kari Brendtro, Richard Carroll, Sean Cleary, Michelle Kim, Grace Kong, Calvin Law, Ben Lawrence, Alexander McEwan, Caitlin McGregor, Michael Michael, Janice Pasieka, Nick PavlakisRodney Pommier, Michael Soulen, David Wyld, Eva Segelov

    Research output: Contribution to journalArticle

    4 Citations (Scopus)

    Abstract

    There is no consensus on optimal follow-up for completely resected gastroenteropancreatic neuroendocrine tumors. Published guidelines for follow-up are complex and emphasize closer surveillance in the first 3 years after resection. Neuroendocrine tumors have a different pattern and timescale of recurrence, and thus require more practical and tailored follow-up. The Commonwealth Neuroendocrine Tumour Collaboration convened an international multidisciplinary expert panel, in collaboration with the North American Neuroendocrine Tumor Society, to create patient-centered follow-up recommendations for completely resected gastroenteropancreatic neuroendocrine tumors. This panel used the RAND/UCLA (University of California, Los Angeles) Appropriateness Method to generate recommendations. A large international survey was conducted outlining current the surveillance practice of neuroendocrine tumor practitioners and shortcomings of the current guidelines. A systematic review of available data to date was supplemented by recurrence data from 2 large patient series. The resultant guidelines suggest follow-up for at least 10 years for fully resected small-bowel and pancreatic neuroendocrine tumors and also identify clinical situations in which no follow-up is required. These recommendations stratify follow-up strategies based on evidence-based prognostic factors that allow for a more individualized patient-centered approach to this complex and heterogeneous malignant neoplasm..

    Original languageEnglish (US)
    JournalJAMA oncology
    DOIs
    StateAccepted/In press - Jan 1 2018

    Fingerprint

    Neuroendocrine Tumors
    Guidelines
    Recurrence
    Los Angeles
    Gastro-enteropancreatic neuroendocrine tumor
    Neoplasms

    ASJC Scopus subject areas

    • Oncology
    • Cancer Research

    Cite this

    Singh, S., Moody, L., Chan, D. L., Metz, D. C., Strosberg, J., Asmis, T., ... Segelov, E. (Accepted/In press). Follow-up Recommendations for Completely Resected Gastroenteropancreatic Neuroendocrine Tumors. JAMA oncology. https://doi.org/10.1001/jamaoncol.2018.2428

    Follow-up Recommendations for Completely Resected Gastroenteropancreatic Neuroendocrine Tumors. / Singh, Simron; Moody, Lesley; Chan, David L.; Metz, David C.; Strosberg, Jonathan; Asmis, Timothy; Bailey, Dale L.; Bergsland, Emily; Brendtro, Kari; Carroll, Richard; Cleary, Sean; Kim, Michelle; Kong, Grace; Law, Calvin; Lawrence, Ben; McEwan, Alexander; McGregor, Caitlin; Michael, Michael; Pasieka, Janice; Pavlakis, Nick; Pommier, Rodney; Soulen, Michael; Wyld, David; Segelov, Eva.

    In: JAMA oncology, 01.01.2018.

    Research output: Contribution to journalArticle

    Singh, S, Moody, L, Chan, DL, Metz, DC, Strosberg, J, Asmis, T, Bailey, DL, Bergsland, E, Brendtro, K, Carroll, R, Cleary, S, Kim, M, Kong, G, Law, C, Lawrence, B, McEwan, A, McGregor, C, Michael, M, Pasieka, J, Pavlakis, N, Pommier, R, Soulen, M, Wyld, D & Segelov, E 2018, 'Follow-up Recommendations for Completely Resected Gastroenteropancreatic Neuroendocrine Tumors', JAMA oncology. https://doi.org/10.1001/jamaoncol.2018.2428
    Singh, Simron ; Moody, Lesley ; Chan, David L. ; Metz, David C. ; Strosberg, Jonathan ; Asmis, Timothy ; Bailey, Dale L. ; Bergsland, Emily ; Brendtro, Kari ; Carroll, Richard ; Cleary, Sean ; Kim, Michelle ; Kong, Grace ; Law, Calvin ; Lawrence, Ben ; McEwan, Alexander ; McGregor, Caitlin ; Michael, Michael ; Pasieka, Janice ; Pavlakis, Nick ; Pommier, Rodney ; Soulen, Michael ; Wyld, David ; Segelov, Eva. / Follow-up Recommendations for Completely Resected Gastroenteropancreatic Neuroendocrine Tumors. In: JAMA oncology. 2018.
    @article{3129e2e5d95441e0883f0a7740cf9700,
    title = "Follow-up Recommendations for Completely Resected Gastroenteropancreatic Neuroendocrine Tumors",
    abstract = "There is no consensus on optimal follow-up for completely resected gastroenteropancreatic neuroendocrine tumors. Published guidelines for follow-up are complex and emphasize closer surveillance in the first 3 years after resection. Neuroendocrine tumors have a different pattern and timescale of recurrence, and thus require more practical and tailored follow-up. The Commonwealth Neuroendocrine Tumour Collaboration convened an international multidisciplinary expert panel, in collaboration with the North American Neuroendocrine Tumor Society, to create patient-centered follow-up recommendations for completely resected gastroenteropancreatic neuroendocrine tumors. This panel used the RAND/UCLA (University of California, Los Angeles) Appropriateness Method to generate recommendations. A large international survey was conducted outlining current the surveillance practice of neuroendocrine tumor practitioners and shortcomings of the current guidelines. A systematic review of available data to date was supplemented by recurrence data from 2 large patient series. The resultant guidelines suggest follow-up for at least 10 years for fully resected small-bowel and pancreatic neuroendocrine tumors and also identify clinical situations in which no follow-up is required. These recommendations stratify follow-up strategies based on evidence-based prognostic factors that allow for a more individualized patient-centered approach to this complex and heterogeneous malignant neoplasm..",
    author = "Simron Singh and Lesley Moody and Chan, {David L.} and Metz, {David C.} and Jonathan Strosberg and Timothy Asmis and Bailey, {Dale L.} and Emily Bergsland and Kari Brendtro and Richard Carroll and Sean Cleary and Michelle Kim and Grace Kong and Calvin Law and Ben Lawrence and Alexander McEwan and Caitlin McGregor and Michael Michael and Janice Pasieka and Nick Pavlakis and Rodney Pommier and Michael Soulen and David Wyld and Eva Segelov",
    year = "2018",
    month = "1",
    day = "1",
    doi = "10.1001/jamaoncol.2018.2428",
    language = "English (US)",
    journal = "JAMA oncology",
    issn = "2374-2437",
    publisher = "American Medical Association",

    }

    TY - JOUR

    T1 - Follow-up Recommendations for Completely Resected Gastroenteropancreatic Neuroendocrine Tumors

    AU - Singh, Simron

    AU - Moody, Lesley

    AU - Chan, David L.

    AU - Metz, David C.

    AU - Strosberg, Jonathan

    AU - Asmis, Timothy

    AU - Bailey, Dale L.

    AU - Bergsland, Emily

    AU - Brendtro, Kari

    AU - Carroll, Richard

    AU - Cleary, Sean

    AU - Kim, Michelle

    AU - Kong, Grace

    AU - Law, Calvin

    AU - Lawrence, Ben

    AU - McEwan, Alexander

    AU - McGregor, Caitlin

    AU - Michael, Michael

    AU - Pasieka, Janice

    AU - Pavlakis, Nick

    AU - Pommier, Rodney

    AU - Soulen, Michael

    AU - Wyld, David

    AU - Segelov, Eva

    PY - 2018/1/1

    Y1 - 2018/1/1

    N2 - There is no consensus on optimal follow-up for completely resected gastroenteropancreatic neuroendocrine tumors. Published guidelines for follow-up are complex and emphasize closer surveillance in the first 3 years after resection. Neuroendocrine tumors have a different pattern and timescale of recurrence, and thus require more practical and tailored follow-up. The Commonwealth Neuroendocrine Tumour Collaboration convened an international multidisciplinary expert panel, in collaboration with the North American Neuroendocrine Tumor Society, to create patient-centered follow-up recommendations for completely resected gastroenteropancreatic neuroendocrine tumors. This panel used the RAND/UCLA (University of California, Los Angeles) Appropriateness Method to generate recommendations. A large international survey was conducted outlining current the surveillance practice of neuroendocrine tumor practitioners and shortcomings of the current guidelines. A systematic review of available data to date was supplemented by recurrence data from 2 large patient series. The resultant guidelines suggest follow-up for at least 10 years for fully resected small-bowel and pancreatic neuroendocrine tumors and also identify clinical situations in which no follow-up is required. These recommendations stratify follow-up strategies based on evidence-based prognostic factors that allow for a more individualized patient-centered approach to this complex and heterogeneous malignant neoplasm..

    AB - There is no consensus on optimal follow-up for completely resected gastroenteropancreatic neuroendocrine tumors. Published guidelines for follow-up are complex and emphasize closer surveillance in the first 3 years after resection. Neuroendocrine tumors have a different pattern and timescale of recurrence, and thus require more practical and tailored follow-up. The Commonwealth Neuroendocrine Tumour Collaboration convened an international multidisciplinary expert panel, in collaboration with the North American Neuroendocrine Tumor Society, to create patient-centered follow-up recommendations for completely resected gastroenteropancreatic neuroendocrine tumors. This panel used the RAND/UCLA (University of California, Los Angeles) Appropriateness Method to generate recommendations. A large international survey was conducted outlining current the surveillance practice of neuroendocrine tumor practitioners and shortcomings of the current guidelines. A systematic review of available data to date was supplemented by recurrence data from 2 large patient series. The resultant guidelines suggest follow-up for at least 10 years for fully resected small-bowel and pancreatic neuroendocrine tumors and also identify clinical situations in which no follow-up is required. These recommendations stratify follow-up strategies based on evidence-based prognostic factors that allow for a more individualized patient-centered approach to this complex and heterogeneous malignant neoplasm..

    UR - http://www.scopus.com/inward/record.url?scp=85052725843&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=85052725843&partnerID=8YFLogxK

    U2 - 10.1001/jamaoncol.2018.2428

    DO - 10.1001/jamaoncol.2018.2428

    M3 - Article

    C2 - 30054622

    AN - SCOPUS:85052725843

    JO - JAMA oncology

    JF - JAMA oncology

    SN - 2374-2437

    ER -